Table 4.
Survival on breast IMPC and IDC in previous seven reports and the present study
| Author | Median follow-up (month) | OS (IMPC vs IDC) | FFS (IMPC vs IDC) | LRFS (IMPC vs IDC) | DMFS (IMPC vs IDC) |
|---|---|---|---|---|---|
| Chen [4] | 60.1 | 59 vs 77 % P = 0.004 |
/ | 88.8 vs 96 % P = 0.055 |
61.2 vs 72 % P = 0.108 |
| Yu [8] | 45.0 | 86 vs 87.7 % P = 0.18 |
/ | 68.2 vs 81.4 % P = 0.045 |
78.1 vs 79.3 % P = 0.86 |
| Vingiani [14] | 51.0 | 89.8 vs 90.8 % P = 0.8 |
75.5 vs 79.6 % P = 0.47 |
/ | / |
| Liu [9] | 68.4 | / | 84.3 vs 78.4 % P = 0.518 |
/ | / |
| Shi [7] | 40.5 | 75.9 vs 89.5 % P = 0.001 |
67.1 vs 84.5 % P < 0.001 |
/ | / |
| Chen [10] | 48.0 | 82.9 vs 80.5 % P = 0.52 |
/ | / | / |
| Yu [16] | 59.0 | 97.7 vs 95.7 % P = 0.67 |
/ | 91.8 vs 96.3 % P = 0.03 |
/ |
| Present study | 39.0 | 97 vs 94.2 % P = 0.78 |
87.9 vs 86.2 % P = 0.91 |
93.9 vs 89.0 % P = 0.82 |
90.9 vs 89 % P = 0.97 |
IMPC invasive micropapillary carcinoma, IDC invasive ductal carcinoma, OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival, FFS failure-free survival